Suzhou Basecare Medical Corporation Limited (HKG:2170)

Market Cap	560.73M
Revenue (ttm)	302.12M
Net Income (ttm)	-261.45M
Shares Out	273.53M
EPS (ttm)	-0.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	115,500
Average Volume	169,400
Open	1.990
Previous Close	2.050
Day's Range	1.960 - 2.030
52-Week Range	1.810 - 4.450
Beta	0.20
RSI	43.95
Earnings Date	Mar 27, 2026

About HKG:2170

Suzhou Basecare Medical Corporation Limited, an investment holding company provides genetic testing solutions for assisted human reproduction in the People’s Republic of China and Australia. The company offers pre-implantation genetic test kits, including PGT-A kit to detect aneuploidy; PGT-M kit to detect single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kit to detect chromosome structural rearrangements, which are common causes of recurrent miscarriage. It also provides DA500, a high-throughput gene sequencer that provi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 497
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2170

Financial Performance

In 2024, HKG:2170's revenue was 299.11 million, an increase of 43.82% compared to the previous year's 207.98 million. Losses were -237.03 million, 23.7% more than in 2023.

Financial numbers in CNY